Prof. Yiping Zhang 张沂平
Chief Physician, Professor
Department of Medical Oncology for Thoracic Tumors, Zhejiang Cancer Hospital, Hangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Medical oncology for lung, breast, gastric cancers and malignant lymphoma. Focuses on multidisciplinary care for chest tumors, including lung and esophageal cancer, using chemotherapy and targeted therapy.
Dr. Zhang has over 30 years of experience in medical oncology. A professor and master's supervisor, Dr. Zhang has published over 70 papers, including more than 20 SCI articles as corresponding author. Dr. Zhang served as principal or participating investigator in over 40 multicenter clinical trials, such as IPASS and OPTIMAL, and leads over 10 provincial-level research projects.
Professional roles
- Standing Committee Member, Clinical Oncology Collaboration Professional Committee, China Anti-Cancer Association (CSCO)
- Standing Committee Member, Oncology Branch, Chinese Medical Doctor Association
- Member, Clinical Chemotherapy Professional Committee, China Anti-Cancer Association
- Member, Anti-cancer Drug Professional Committee, China Anti-Cancer Association
Name order: in Chinese the family name comes first (Zhang Yiping). Papers usually list the name as Yiping Zhang or Zhang Y.
Selected publications
184 papers on PubMed matched by name and affiliation; 30 as first or senior author since 2016. Most recent first- or senior-author papers:
- Innovation (Camb), 2026 (first author): International guidelines on the diagnosis and treatment of NUT carcinoma. PubMed 41737331
- Contrast Media Mol Imaging, 2022 (senior author): The Clinical Efficacy and Economic Benefits of Recombinant Human Thrombopoietin for the Treatment of Chemotherapy or Chemoradiotherapy-Induced Thrombocytopenia. PubMed 35909587
- BMC Med, 2022 (senior author): Apatinib in patients with recurrent or metastatic thymic epithelial tumor: a single-arm, multicenter, open-label, phase II trial. PubMed 35534877
- BMC Med, 2022 (senior author): Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trial. PubMed 35101045
- Ann Palliat Med, 2021 (senior author): Clinical efficacy and safety of mecapegfilgrastim in small cell lung cancer as primary prophylaxis of neutropenia post chemotherapy: a retrospective analysis. PubMed 34353071
- J Thorac Dis, 2020 (senior author): PD-L1 expression in malignant pleural effusion samples and its correlation with oncogene mutations in non-small cell lung cancer. PubMed 32395276
- Lung Cancer, 2019 (senior author): Cytological-negative pleural effusion can be an alternative liquid biopsy media for detection of EGFR mutation in NSCLC patients. PubMed 31421258
- Onco Targets Ther, 2019 (senior author): The efficacy and safety of anlotinib treatment for advanced lung cancer. PubMed 31616163
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion